Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...

And it’s not because my diagnosis changed. When I left the hospital, my clinicians said I had atypical hemolytic uremic syndrome, or aHUS. However, there’s a movement to call it complement ...

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized ...

Fabhalta is also being studied in a broad range of rare kidney diseases, including atypical hemolytic uremic syndrome (aHUS), immune complex membranoproliferative glomerulonephritis (IC-MPGN ...

Atypical Hemolytic Uremic Syndrome Market Outlook 2025-2035: The 7 major Atypical Hemolytic Uremic Syndrome markets are expected to exhibit a CAGR of 4.1% during 2025-2035. There is growth in the ...

To guide them through an aHUS diagnosis and subsequent treatment, Alexion Pharmaceuticals has released an interactive storybook aimed at “demystifying” the disease for 6- to 10-year-olds ...

Marks a significant advancement in offering new treatment options for patients with rare diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and ...

EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS ...

When tested on Investigational New Drug products (n=7), both complement-dependent hemolysis and monocyte monolayer assays effectively detected elevated hemolytic activity. The Food and Drug ...

These include: Note: Soliris is also used to treat aHUS in children ages 2 months and older. Soliris isn’t used to treat HUS triggered byE. coli infection. The active ingredient in Soliris is ...